Ergoteles’s Olema Pharmaceuticals OLMA Stock Holding History

Ergoteles’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,906	Closed	-$95.3K	–	1622
2022 Q4	$95.3K	Buy	+38,906	New	+$113K	﹤0.01%	1230
2022 Q3	–	Sell	-124,900	Closed	-$508K	–	1855
2022 Q2	$508K	Buy	124,900 +111,700	+846%	+$354K	0.02%	829
2022 Q1	$56K	Sell	13,200 -20,800	-61%	-$115K	﹤0.01%	1149
2021 Q4	$318K	Buy	+34,000	New	+$704K	0.01%	831

Other funds holding OLMA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's OLMA Position: Q1 2023 in Review

Ergoteles sold out of Olema Pharmaceuticals (OLMA) in Q1 2023, closing a stake of 38,906 shares — an estimated $95.3K sold.

Ergoteles first reported a position in OLMA in Q4 2021 and held it in 4 quarters. The position peaked at $508K in Q2 2022. 65 funds tracked by Wall St. Rank hold OLMA as of Q1 2023.

Ergoteles reported no remaining Olema Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 38,906 Olema Pharmaceuticals shares in Q1 2023, an estimated $95.3K.
Ergoteles first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Ergoteles's Olema Pharmaceuticals position peaked at $508K in Q2 2022.
65 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.